Rybelsus Side Effects: Withdrawal and Discontinuation Syndrome Explained

Is there a withdrawal syndrome with Rybelsus?

Withdrawal, in the sense the word carries for opioids and benzodiazepines, means a set of symptoms that appear when a drug the body has adapted to is taken away. Semaglutide is a GLP-1 receptor agonist: it activates the GLP-1 receptor, slows gastric emptying and increases insulin release when blood glucose is high.

The Rybelsus prescribing information, which also covers Ozempic tablets, lists its adverse reactions as events during treatment, and notes that most reports of nausea, vomiting and diarrhea happened during dose escalation [1]. The label contains no mention of withdrawal or dependence.

What the label lists while you are taking it

The label's pooled analysis of two placebo-controlled trials in type 2 diabetes (362 people on placebo, 356 on 7 mg and 356 on 14 mg) gives these rates for the most common reactions: nausea 6%, 11% and 20%; abdominal pain 4%, 10% and 11%; diarrhea 4%, 9% and 10%; decreased appetite 1%, 6% and 9%; vomiting 3%, 6% and 8%; constipation 2%, 6% and 5% [1].

Gastrointestinal reactions of any kind occurred in 21% on placebo, 32% on 7 mg and 41% on 14 mg, and severe GI reactions in 0.3%, 0.6% and 2.0% respectively. Treatment was stopped for GI reasons in 1% on placebo, 4% on 7 mg and 8% on 14 mg [1].

In the 4-year cardiovascular outcomes trial, 4,825 people were randomized to semaglutide tablets and 4,825 to placebo. Study drug was permanently discontinued because of an adverse event in 15.5% of the semaglutide tablet group and 11.6% of the placebo group [1].

All of those are on-treatment numbers: reactions while taking the drug, and reasons for stopping it. They are not a description of what happens after it clears.

What changes when the tablet stops

Semaglutide has an extended half-life of approximately 1 week [2]. The label says to discontinue Rybelsus in women at least 2 months before a planned pregnancy because of the long washout period for semaglutide [1].

Weight after stopping injectable semaglutide

The off-treatment weight data come from weekly subcutaneous semaglutide 2.4 mg in adults with obesity and no diabetes, not from Rybelsus tablets. In an extension of the STEP 1 trial, 327 of the 1,961 people in the main trial took part. Mean weight loss from week 0 to week 68 was 17.3% on semaglutide and 2.0% on placebo. One year after treatment stopped, the semaglutide group had regained 11.6 percentage points, for a net loss of 5.6% from baseline at week 120, compared with 0.1% for placebo, and most cardiometabolic improvements had moved back toward baseline [3].

STEP 4 tested the same question directly. After a 20-week run-in, 803 adults who had reached 2.4 mg were randomized to keep taking it (535 people) or switch to placebo (268) for 48 weeks. From week 20 to week 68, weight changed by -7.9% in those who continued and +6.9% in those switched to placebo [4].

Does the tablet behave differently from the injection?

Rybelsus and Ozempic tablets are not substitutable milligram for milligram [1]. Tablet absorption depends on the SNAC component built into the tablet, which helps semaglutide be absorbed, mainly in the stomach [7].

When the label says to stop

The label says to discontinue Rybelsus if pancreatitis is suspected or a serious hypersensitivity reaction occurs [1]. For suspected gallbladder disease, it says gallbladder studies are indicated; for dehydration-related kidney concerns or a history of retinopathy, it calls for monitoring [1].

• Acute pancreatitis: the label says to discontinue if pancreatitis is suspected and begin appropriate management [1].
• Serious hypersensitivity: anaphylaxis and angioedema have been reported, and the label says to discontinue and monitor until signs and symptoms resolve [1].
• Gallbladder disease: if cholelithiasis or cholecystitis is suspected, gallbladder studies are indicated [1].
• Acute kidney injury from volume depletion: renal function should be monitored in people with reactions such as vomiting or diarrhea that can cause dehydration, especially during dose initiation and escalation [1].
• Diabetic retinopathy: people with a history should be monitored for progression; in a pooled analysis of glycemic control trials, retinopathy-related adverse reactions were reported in 4.2% on semaglutide tablets and 3.8% on comparator [1].

In Europe, EMA's safety committee concluded in June 2025 that NAION, a sudden optic nerve-related vision loss, is a very rare side effect of semaglutide medicines including Rybelsus (up to 1 in 10,000 people) and advised stopping semaglutide if NAION is confirmed [8].

Before surgery

The label warns that pulmonary aspiration during general anesthesia or deep sedation has been reported with GLP-1 receptor agonists, and tells patients to inform healthcare providers about any planned surgery or procedure [1].